stockrow
Saturday 7 November 2026
Export NKGN’s income statement to Excel — free account
NKGen Biotech, Inc.
NKGN Healthcare Biotechnology
NKGen Biotech, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $77,000.00.
- EPS
- +232.0%
- Free cash flow
- +28.7%
Quarter to March 2025, against a year earlier
0.01
0.00
0.00%
Follow NKGN
Alert me
| Older periods | Jun '24 | Sep '24 | Dec '24 | Mar '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
225.55% | 111.23% | 68.87% | 44.70% | |
| (222.71%) | (242.67%) | (270.76%) | (146.49%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
243.10% | 215.50% | 104.91% | 82.69% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.89) | (0.72) | (0.72) | (0.43) | |
Free Cash Flow |
(21.53) | (20.88) | (20.89) | (19.75) | |
Capital Expenditures |
0.00 | (0.01) | (0.01) | (0.10) | |
| Other line items | |||||
Cash ROIC |
41.63% | 78.80% | 79.82% | 95.27% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(13.28) | (11.92) | (9.90) | (11.10) | |
Operating CF/Net income |
0.24 | 0.43 | 0.47 | 0.83 | |
Depreciation/Fixed assets |
0.09 | 0.09 | 0.10 | 0.11 | |
Capex/Depreciation |
0.00 | (0.01) | (0.01) | (0.07) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.89) | (0.72) | (0.72) | (0.43) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026